Showing 3561-3570 of 5662 results for "".
- Dong-A ST: Phase 3 Trial Shows Therapeutic Equivalence Between Plaque Psoriasis Drug Candidate DMB-3115 and Stelarahttps://practicaldermatology.com/news/dong-a-st-demonstrates-therapeutic-equivalence-between-plaque-psoriasis-drug-candidate-dmb-3115-and-stelara-in-phase-3-trial/2461504/South Korea-based Dong-A ST announced that therapeutic equivalence and safety were established between DMB-3115 and Stelara (ustekinumab; Janssen Biotech), the reference drug, in global phase 3 trials. Stelara is indicated for plaque psoriasis, psoriatic arthritis,
- Investigational Topical Peptide May Help Tame Eczemahttps://practicaldermatology.com/news/investigational-topical-peptide-may-help-tame-eczema/2461503/A new investigational topical peptide may can block inflammatory signaling in a preclinical model of atopic dermatitis – eczema, researchers at Vanderbilt University Medical Center (VUMC) report. Treatment for severe cases of eczema includes immunosuppressive drugs
- AAD Issues Updated Guidelines for the Management of Atopic Dermatitis in Adults with Topical Therapieshttps://practicaldermatology.com/news/aad-issues-updated-guidelines-for-the-management-of-atopic-dermatitis-in-adults-with-topical-therapies/2461499/The American Academy of Dermatology (AAD) has published updated guidelines of care for the management of atopic dermatitis in adults with topical therapies in the Journal of the American Academy
- Hyphens Pharma Licenses Winlevi for 10 ASEAN Countries from Cosmo Pharmaceuticalshttps://practicaldermatology.com/news/hyphens-pharma-licenses-winlevi-for-10-asean-countries-from-cosmo-pharmaceuticals/2461475/Hyphens Pharma International Limited’s subsidiary Hyphens Pharma Pte. Ltd. has entered into exclusive license and supply agreements with Cassiopea S.p.A to develop and commercialize Winlevi (clascoterone) cream 1% and all future product extensions and/or improvemenst in the treat
- Hydrafacial, DOCTOR BABOR Collab for New Collagen HA Boosterhttps://practicaldermatology.com/news/hydrafacial-doctor-babor-collab-for-new-collagen-ha-booster/2461461/The Beauty Health Company’s Hydrafacial launched a new booster co-created with BABOR Skincare. The new DOCTOR BABOR Collagen HA booster is inspired by DOCTOR BABOR’s formulations and developed with the BABOR Laboratories in Germany. “Hydrafacial has cre
- Study: Isolated Nail PsO Not Linked to Metabolic Syndrome Riskhttps://practicaldermatology.com/news/study-isolated-nail-psoriasis-not-linked-to-metabolic-syndrome-risk/2461456/Isolated nail psoriasis does not increase risk for metabolic syndrome, according to a letter to the editor in the Journal of the European Academy of Dermatology & Venereology. The analysis include
- AD News: Alphyn Biologics Completes First Cohort of Phase2a Clinical Trial of Topical Therapyhttps://practicaldermatology.com/news/ad-news-alphyn-biologics-completes-first-cohort-of-phase2a-clinical-trial-of-topical-therapy-1/2461432/Alphyn Biologics completed the first cohort of its Phase2a clinical trial of AB-101a, a topical therapeutic candidate for mil
- Revance Shares Two Publications in The Aesthetic Surgery Journal That Advance Glabellar Line Injection Technique and Assessmenthttps://practicaldermatology.com/news/revance-shares-two-publications-in-the-aesthetic-surgery-journal-that-advance-glabellar-line-injection-technique-and-assessment/2461425/Two peer-reviewed articles in the Aesthetic Surgery Journal, the official journal of The Aesthetic Society, highlight the nuances of glabellar line injection technique and aim to improve patient outcomes, irrespective of the neuromodulator used. The
- High Rates of Skin Conditions Seen Among Urban-living Indigenous Kids in High-Income Countrieshttps://practicaldermatology.com/news/high-rates-of-skin-conditions-seen-among-urban-living-indigenous-kids-in-high-income-countries/2461421/Many urban-living Indigenous children and young people in high-income countries are burdened with atopic dermatitis and bacterial skin infections, according to Aasystematic analysis in Pediatric Dermatology. Invest
- USPTO Grants Patents to TOOsonix A/S for HIFU Technologies in Dermatologyhttps://practicaldermatology.com/news/uspto-grants-patents-to-toosonix-as-for-hifu-technologies-in-dermatology/2461420/The United States Patent and Trademark Office (USPTO) granted TOOsonix A/S patents regarding its key high-intensity focused ultrasound (HIFU) technologies for dermatology The U.S. patent and already granted patents in Europe and China to complete the first phase of securing intellectual prop